Publications by authors named "Gloria Garcia Donas"
Platelet Responses After Tapering and Discontinuation of Fostamatinib in Patients with Immune Thrombocytopenia: A Continuation of the Fostasur Study.
J Clin Med
October 2024
Article Synopsis
- Fostamatinib is an approved treatment for adults with chronic immune thrombocytopenia (ITP) but there's limited research on tapering doses and achieving remission after stopping the drug.
- A study involving 61 patients examined the safety and effectiveness of fostamatinib during and after dose tapering, noting that complete platelet response was typically achieved within 28 days.
- Results showed that most patients maintained platelet counts above 100 × 10/L after discontinuation, with a low relapse rate, suggesting that tapering could lead to sustained remission, though further research on tapering strategies is needed.
Article Synopsis
- Avatrombopag is a newly approved treatment for immune thrombocytopenia (ITP), with limited real-world effectiveness and safety data available.
- A study by the Spanish ITP Group involving 268 patients showed that 90.1% of those with low platelet counts improved significantly after starting the drug, with many achieving stable platelet levels.
- The treatment allowed most patients to reduce or stop corticosteroid use, and only a small percentage experienced thrombocytosis or thromboembolic events, indicating its potential as an effective management option for ITP.
Objective: Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real-world setting have not often been addressed.
Methods: We report the experience of Spanish reference centers for coagulation disorders and from acquired hemophilia Spanish Registry (AHASR) from August 2012 to February 2021.
Severe hemorrhagic events occur in a significant fraction of acute promyelocytic leukemia patients, either at presentation and/or early after starting therapy, leading to treatment failure and early deaths. However, identification of independent predictors for high-risk of severe bleeding at diagnosis, remains a challenge. Here, we investigated the immunophenotype of bone marrow leukemic cells from 109 newly diagnosed acute promyelocytic leukemia patients, particularly focusing on the identification of basophil-related features, and their potential association with severe bleeding episodes and patient overall survival.
View Article and Find Full Text PDFParoxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disease. With the advent of eculizumab treatment, renal function has substantially improved, although no data from real-world clinical practice are available. An observational, retrospective, multicenter study was conducted in Spain on clinical data obtained from outpatient visits of patients with PNH (Spanish PNH Registry) who had experienced acute (ARF) or chronic (CRF) renal failure.
View Article and Find Full Text PDF